Recursion Pharmaceuticals, Inc. (RXRX) Stock Grade

About Recursion Pharmaceuticals, Inc.'s fundamentals

Recursion Pharmaceuticals is a biotechnology company with a market capitalization of $1.9 billion that demonstrated strong revenue growth of 26.9% year-over-year, indicating expanding business activity. However, the company operates at a significant loss, with a net margin of -863.4%, and reported a net loss in its latest annual statement, reflecting the typical cash-burn pattern of early-stage drug development companies. The company does not currently pay a dividend. These metrics show a growth-stage biotech firm that is investing heavily in research and development while working toward profitability.